drugset
drugset / Trial / NCT01956903

Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.

NCT01956903 ↗

Phase 1/2 Completed 15 enrolled Grupo Espanol de trasplantes hematopoyeticos y terapia celular
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of sequential infusion of allogenic mesenchymal stem cells (MSC) expanded "in vitro" in treating patients with acute graft-versus-host disease refractory to first-line therapy.

Timeline

Start
2010-01
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogenic Mesenchymal Stem Cell Cell therapy 700000 cells/kg —

Indications

chronic graft versus host disease